Investigating factors affecting survival rates in African American women with ER+ breast cancer

Who could benefit from this research

What this research studies

This research focuses on understanding why African American women with estrogen receptor positive (ER+) breast cancer have worse survival rates compared to their white counterparts. The study aims to identify biological mechanisms, particularly the role of the enzyme SQLE, that may contribute to this disparity. By analyzing tumor samples and patient data, the researchers hope to uncover why these patients experience resistance to standard endocrine therapies. The findings could lead to improved treatment strategies tailored for African American women facing ER+ breast cancer.

Why it matters

Where this research is happening

• University of Illinois at Chicago
  Chicago, United States Active

Researchers

• Principal investigator: Coloff, Jonathan L. — University of Illinois at Chicago
• Study coordinator: Coloff, Jonathan L.

Related research

Other NIH-funded projects on the same topics.

• ER+ Breast Cancer Bone Metastasis in a Real Body Environment

  This grant aims to understand why estrogen receptor alpha–positive breast cancer often spreads to bone and how the bone environment and immune system affect treatment resistance.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11422333

• Targeting RAGE to fight obesity-related ER+ breast cancer and its drug resistance

  A scientist team will explore how obesity-related inflammation involving RAGE and estrone interacts with ER+ breast cancer to drive growth and spread, aiming to find strategies to overcome therapy resistance.

  NIH research Georgetown University · Washington, United States · NIH-11364105

• Understanding estrogen signals in bone to stop ER+ breast cancer spread

  This NIH grant aims to uncover how estrogen signals inside bone help ER-positive breast cancer cells grow and spread, with the goal of finding better ways to prevent bone metastasis.

  NIH research University of Arizona · Tucson, United States · NIH-11364029

• Progesterone Receptor Signaling and Dormancy in ER+ Breast Cancer

  Researchers are studying how hormone signals in ER+/PR+ breast cancer influence cancer cell dormancy and later recurrence.

  NIH research University of Minnesota · Minneapolis, United States · NIH-11363974

• Heavy Metals and Breast Cancer Treatment Resistance

  This project explores how exposure to heavy metals might make ER+ breast cancer harder to treat and how we might overcome this challenge.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11349797

• Turning ER-positive breast cancer into a viral target for immune attack

  This project aims to wake up viral-like bits inside ER-positive breast cancer cells so the immune system can spot and attack them.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11308203

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.